Hanson & Doremus Investment Management Gilead Sciences, Inc. Transaction History

Hanson & Doremus Investment Management

$794 Million
Q3 2025

A detailed history of Hanson & Doremus Investment Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Hanson & Doremus Investment Management holds 2,256 shares of GILD stock, worth $266,884. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,256

Previous 2,744 17.78%

Holding current value

$266,884

Previous $304,000 17.76%

% of portfolio

0.03%

Previous 0.04%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 15, 2025	SELL	$108.22 - $120.47 $52,811 - $58,789	-488 Reduced 17.78%	2,256 $250,000
Q1 2025 Apr 17, 2025	BUY	$89.14 - $117.41 $222,850 - $293,525	2,500 Added 1024.59%	2,744 $307,000
Q3 2024 Oct 17, 2024	SELL	$66.59 - $83.99 $8,323 - $10,498	-125 Reduced 33.88%	244 $20,000
Q2 2024 Aug 08, 2024	SELL	$63.15 - $72.88 $116,638 - $134,609	-1,847 Reduced 83.35%	369 $25,000
Q1 2024 Apr 22, 2024	BUY	$71.58 - $87.29 $8,947 - $10,911	125 Added 5.98%	2,216 $162,000
Q3 2023 Oct 24, 2023	BUY	$73.94 - $80.67 $3,697 - $4,033	50 Added 2.45%	2,091 $156,000
Q3 2022 Oct 20, 2022	SELL	$59.54 - $68.01 $52,157 - $59,576	-876 Reduced 30.03%	2,041 $126,000
Q2 2022 Jul 19, 2022	SELL	$57.72 - $65.01 $19,624 - $22,103	-340 Reduced 10.44%	2,917 $180,000
Q1 2022 Apr 22, 2022	SELL	$57.92 - $72.58 $55,719 - $69,821	-962 Reduced 22.8%	3,257 $194,000
Q4 2021 Jan 20, 2022	SELL	$64.88 - $73.64 $40,744 - $46,245	-628 Reduced 12.96%	4,219 $306,000
Q3 2021 Oct 21, 2021	SELL	$67.69 - $73.03 $57,536 - $62,075	-850 Reduced 14.92%	4,847 $338,000
Q2 2021 Jul 22, 2021	SELL	$63.47 - $69.35 $8,949 - $9,778	-141 Reduced 2.42%	5,697 $360,000
Q1 2021 May 03, 2021	BUY	$60.0 - $68.46 $2,160 - $2,464	36 Added 0.62%	5,838 $377,000
Q4 2020 Feb 01, 2021	BUY	$56.65 - $64.55 $5,948 - $6,777	105 Added 1.84%	5,802 $338,000
Q3 2020 Oct 19, 2020	SELL	$62.1 - $78.08 $5,589 - $7,027	-90 Reduced 1.56%	5,697 $360,000
Q2 2020 Jul 17, 2020	SELL	$72.34 - $84.0 $12,297 - $14,280	-170 Reduced 2.85%	5,787 $445,000
Q1 2020 Apr 24, 2020	SELL	$62.63 - $80.22 $24,926 - $31,927	-398 Reduced 6.26%	5,957 $445,000
Q3 2019 Oct 18, 2019	SELL	$62.51 - $69.0 $18,627 - $20,562	-298 Reduced 4.48%	6,355 $403,000
Q2 2019 Jul 18, 2019	SELL	$61.87 - $69.38 $37,988 - $42,599	-614 Reduced 8.45%	6,653 $449,000
Q1 2019 Apr 23, 2019	BUY	$62.53 - $70.05 $11,818 - $13,239	189 Added 2.67%	7,267 $0
Q4 2018 Jan 31, 2019	BUY	$60.54 - $79.0 $128,526 - $167,717	2,123 Added 42.85%	7,078 $443,000
Q3 2018 Oct 24, 2018	BUY	$71.28 - $78.92 $15,396 - $17,046	216 Added 4.56%	4,955 $0
Q2 2018 Aug 08, 2018	BUY	$64.88 - $75.68 $67,021 - $78,177	1,033 Added 27.87%	4,739 $336,000
Q1 2018 May 10, 2018	BUY	$72.84 - $88.8 $90,685 - $110,556	1,245 Added 50.59%	3,706 $279,000
Q4 2017 Jan 25, 2018	BUY	$71.15 - $83.52 $46,105 - $54,120	648 Added 35.74%	2,461 $176,000
Q3 2017 Oct 26, 2017	BUY	$72.11 - $85.47 $130,735 - $154,957	1,813	1,813 $0

Others Institutions Holding GILD

# of Institutions

2,329

Shares Held

1.03B

Call Options Held

12.1M

Put Options Held

9.13M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $148B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hanson & Doremus Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Hanson & Doremus Investment Management with notifications on news.

Account

Hanson & Doremus Investment Management Gilead Sciences, Inc. Transaction History